Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease

Recruiting Observational Study
Pediatric Non-alcoholic Fatty Liver Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
8 – 18
Sex
Any
Study type
Observational
Participants needed
850 (estimated)
Sponsor
University Hospital, Ghent · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic. Secondary to increasing rates of obesity in children and adolescents, the prevalence of NAFLD has more than doubled in the last decades and is now the most common pediatric liver disease. At present, lifestyle modification by dietary intervention and increasin…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Enrolled in the lifestyle management program for obesity in one of the participating centres Exclusion Criteria: * Syndromic obesity * Evidence of liver disease of other causes (viral, auto-immune, genetic) * Average daily alcohol consumption of \>20g/day * Unvalid screening…
Contacts

Ruth De Bruyne, MD, PhD

003293322966

ruth.debruyne@uzgent.be

CONTACT